Nissay Capital Overview
- Investor Type
- Venture Capital
- Status
- Active
- Investments
- 215
- Portfolio
- 127
- Exits
- 60

Nissay Capital General Information
Description
Nissay Capital is a venture capital firm wholly owned by Japan's largest life insurance business, Nippon Life Insurance Company. Nissay Capital seeks to invest in early and growth stage businesses across multiple sectors and markets. Nissay has invested in over 1,200 unlisted companies with a total of 226 IPOs achieved since its inception in 1991.
Contact Information
Website
Year Founded
1991
Investor Status
Actively Seeking New Investments
Trade Association
Principles for Responsible Investment (PRI)
Primary Investor Type
Venture Capital
Primary Office
- 8th Floor, Nissay Nagatacho Building
- 2-4-8 Nagatacho Chiyoda-ku
- Tokyo, 100-0014
- Japan
+81 00-0000-0000
Nissay Capital Investments (215)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
---|---|---|---|---|---|---|
Bulk Homme | 11-Sep-2020 | Later Stage VC | 000.00 | Personal Products | Generating Revenue | |
000000 00 00000 | 14-May-2020 | 00000 00000 | 00.000 | Food Products | Generating Revenue | |
00000 | 10-May-2020 | 00000 00000 | 00.000 | Other Healthcare Technology Systems | Generating Revenue | |
000000 | 23-Jan-2020 | 00000 00000 | 00000 | Information Services (B2C) | Generating Revenue | |
0000 (0000 0000000 | 02-Dec-2019 | 00000 00000 | 00.000 | Food Products | Generating Revenue | |
000000000 | 22-Nov-2019 | 00000 00000 | 000.00 | Drug Discovery | Generating Revenue | |
00000000000 | 30-Oct-2019 | 00000 00000 | 00.000 | Horticulture | Generating Revenue | 0000000 000000 |
0000 & 0000000 | 30-Sep-2019 | 00000 00000 | 000.00 | Consumer Finance | Generating Revenue | |
Tribeau | 08-Aug-2019 | Early Stage VC | 00.000 | Information Services (B2C) | Generating Revenue | |
Handii | 25-Jun-2019 | Seed Round | 00.000 | Other Financial Services | Generating Revenue |
Nissay Capital Exits (60)
Company Name | Exit Date | Exit Type | Exit Size |
---|---|---|---|
Kringle Pharma | 28-Dec-2020 | IPO | 00.000 |
00000 | 11-Nov-2020 | 000 00 00000000 | |
00000 | 24-Jun-2020 | 000 | |
00000 000 0000 | 18-Dec-2019 | 000 | |
000000 (00000 0000 | 12-Dec-2019 | 000 | 00000 |
0000000 | 02-Dec-2019 | 000 00 00000000 | |
0000000 000000 | 01-Nov-2019 | 000 00 00000000 | |
000000 | 19-Jun-2019 | 000 | 00000 |
Creo Bioscience | 01-Jun-2019 | Out of Business | |
Makey | 04-Mar-2019 | Merger/Acquisition |
Nissay Capital Investments by Industry, Year, and Region
Investments by Industry

Investments by Year

Investments by Region

PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.
Request a free trialNissay Capital Team (6)
Name | Title | Deals | Funds | Boards | Office |
---|---|---|---|---|---|
Arima Eiji | President & Representative Director | 00 | Tokyo, Japan | ||
Tomoyuki Kasai | Chief Venture Capitalist | 0 | 0 | Tokyo, Japan | |
Junichi Imoto | Senior Venture Capitalist | 0 | 0 | Tokyo, Japan | |
Kensuke Matsuo | Manager, Investment Department | 0 | Tokyo, Japan | ||
Kenko Nagai | Investment Manager | 0 | 0 | Tokyo, Japan |
Nissay Capital Co-Investors (96)
Name | With | Exits | Lead Partner | Series | Industry |
---|---|---|---|---|---|
SMBC Venture Capital | 8 | 0 |
![]() |
![]() |
|
Chibagin Capital | 0 | 0 |
![]() |
![]() |
|
Mitsubishi UFJ Capital | 0 | 0 |
![]() |
![]() |
|
Future Venture Capital | 0 | 0 |
![]() |
![]() |
|
MS&AD Ventures | 0 |
![]() |
![]() |